- Home
- COMM vs EWTX Comparison
COMM vs EWTX Comparison
Compare COMM & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COMM
- EWTX
- Stock Information
- Founded
- COMM 1976
- EWTX 2017
- Country
- COMM United States
- EWTX United States
- Employees
- COMM N/A
- EWTX N/A
- Industry
- COMM Radio And Television Broadcasting And Communications Equipment
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- COMM Technology
- EWTX Health Care
- Exchange
- COMM Nasdaq
- EWTX Nasdaq
- Market Cap
- COMM 1.0B
- EWTX 1.2B
- IPO Year
- COMM 2013
- EWTX 2021
- Fundamental
- Price
- COMM $6.04
- EWTX $14.28
- Analyst Decision
- COMM Hold
- EWTX Buy
- Analyst Count
- COMM 4
- EWTX 8
- Target Price
- COMM $3.50
- EWTX $40.13
- AVG Volume (30 Days)
- COMM 5.9M
- EWTX 1.1M
- Earning Date
- COMM 05-01-2025
- EWTX 05-08-2025
- Dividend Yield
- COMM N/A
- EWTX N/A
- EPS Growth
- COMM N/A
- EWTX N/A
- EPS
- COMM 3.42
- EWTX N/A
- Revenue
- COMM $4,417,100,000.00
- EWTX N/A
- Revenue This Year
- COMM $21.50
- EWTX N/A
- Revenue Next Year
- COMM $8.30
- EWTX N/A
- P/E Ratio
- COMM $236.56
- EWTX N/A
- Revenue Growth
- COMM 16.19
- EWTX N/A
- 52 Week Low
- COMM $1.05
- EWTX $10.60
- 52 Week High
- COMM $7.19
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- COMM 64.05
- EWTX 43.22
- Support Level
- COMM $5.22
- EWTX $13.80
- Resistance Level
- COMM $6.30
- EWTX $14.68
- Average True Range (ATR)
- COMM 0.32
- EWTX 0.78
- MACD
- COMM 0.04
- EWTX 0.08
- Stochastic Oscillator
- COMM 76.26
- EWTX 29.68
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.